share_log

Shanghai Chicmax Cosmetic Co., Ltd. Just Beat EPS By 6.8%: Here's What Analysts Think Will Happen Next

Shanghai Chicmax Cosmetic Co., Ltd. Just Beat EPS By 6.8%: Here's What Analysts Think Will Happen Next

上海Chicmax化妝品有限公司剛剛超過每股收益6.8%:以下是分析師認爲接下來會發生的事情
Simply Wall St ·  03/23 21:14

As you might know, Shanghai Chicmax Cosmetic Co., Ltd. (HKG:2145) just kicked off its latest full-year results with some very strong numbers. Results were good overall, with revenues beating analyst predictions by 3.3% to hit CN¥4.2b. Statutory earnings per share (EPS) came in at CN¥1.16, some 6.8% above whatthe analysts had expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

你可能知道,上海Chicmax化妝品有限公司(HKG: 2145)剛剛以一些非常強勁的數字拉開了其最新的全年業績。總體業績良好,收入比分析師的預期高出3.3%,達到42億元人民幣。法定每股收益(EPS)爲1.16元人民幣,比分析師的預期高出約6.8%。對於投資者來說,盈利是一個重要時刻,因爲他們可以追蹤公司的業績,查看分析師對明年的預測,看看對公司的情緒是否發生了變化。因此,我們收集了最新的業績後預測,以了解估計對明年的預測。

earnings-and-revenue-growth
SEHK:2145 Earnings and Revenue Growth March 24th 2024
SEHK: 2145 2024年3月24日收益和收入增長

After the latest results, the six analysts covering Shanghai Chicmax Cosmetic are now predicting revenues of CN¥6.94b in 2024. If met, this would reflect a huge 66% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to leap 65% to CN¥1.91. Before this earnings report, the analysts had been forecasting revenues of CN¥5.62b and earnings per share (EPS) of CN¥1.57 in 2024. There has definitely been an improvement in perception after these results, with the analysts noticeably increasing both their earnings and revenue estimates.

最新業績公佈後,報道上海Chicmax化妝品的六位分析師現在預測2024年的收入爲69.4億元人民幣。如果得到滿足,這將反映出收入與過去12個月相比大幅增長了66%。預計每股法定收益將增長65%,至1.91元人民幣。在本業績發佈之前,分析師一直預測2024年的收入爲56.2億元人民幣,每股收益(EPS)爲1.57元人民幣。這些業績公佈後,人們的看法肯定有所改善,分析師的收益和收入預期均明顯上升。

With these upgrades, we're not surprised to see that the analysts have lifted their price target 17% to HK$52.51per share. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Shanghai Chicmax Cosmetic analyst has a price target of HK$59.73 per share, while the most pessimistic values it at HK$46.78. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

通過這些上調,分析師將目標股價上調了17%,至每股52.51港元,我們並不感到驚訝。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。最樂觀的上海Chicmax化妝品分析師將目標股價定爲每股59.73港元,而最悲觀的估值爲46.78港元。儘管如此,由於估計範圍如此之窄,這表明分析師對他們認爲該公司的價值有了很好的了解。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Shanghai Chicmax Cosmetic's growth to accelerate, with the forecast 66% annualised growth to the end of 2024 ranking favourably alongside historical growth of 2.0% per annum over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.9% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Shanghai Chicmax Cosmetic is expected to grow much faster than its industry.

我們可以從大局的角度看待這些估計值的另一種方式,例如預測如何與過去的表現相提並論,以及預測相對於業內其他公司是否或多或少看漲。分析師肯定預計上海Chicmax化妝品的增長將加速,預計到2024年底的年化增長率爲66%,而過去三年的歷史年增長率爲2.0%。相比之下,我們的數據表明,預計類似行業的其他公司(有分析師報道)的收入將以每年8.9%的速度增長。考慮到收入增長的預測,很明顯,上海Chicmax化妝品的增長速度預計將比其行業快得多。

The Bottom Line

底線

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Shanghai Chicmax Cosmetic following these results. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

這裏最重要的是,分析師上調了每股收益預期,這表明在這些業績公佈之後,對上海Chicmax Cosmetic的樂觀情緒明顯增強。令人高興的是,他們還上調了收入預期,並預測其增長速度將超過整個行業。我們注意到目標股價已上調,這表明分析師認爲該業務的內在價值可能會隨着時間的推移而提高。

With that in mind, we wouldn't be too quick to come to a conclusion on Shanghai Chicmax Cosmetic. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Shanghai Chicmax Cosmetic analysts - going out to 2025, and you can see them free on our platform here.

考慮到這一點,我們不會很快就上海Chicmax化妝品得出結論。長期盈利能力比明年的利潤重要得多。根據多位上海Chicmax Cosmetic分析師的估計,到2025年,你可以在我們的平台上免費查看。

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Shanghai Chicmax Cosmetic that you should be aware of.

別忘了可能仍然存在風險。例如,我們已經確定了上海Chicmax化妝品的一個警告信號,你應該注意。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論